CBT CABOT CORP

FY2025 10-K
Filed: Nov 24, 2025
Health Care
Miscellaneous Chemical ProductsSEC EDGAR

CABOT CORP (CBT) filed its fiscal year 2025 10-K annual report with the SEC on Nov 24, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • Core business model: Global specialty chemicals and performance materials focused on engineered fine particles for reinforcement and performance applications
  • New product platform launched: EVOLVE® Sustainable Solutions targeting renewable, recovered, and reduced GHG emission products in Reinforcement Materials
+3 more insights

Management Discussion & Analysis

  • Revenue $3.713B, down $281M YoY; Reinforcement Materials sales -$269M to $2.341B, Performance Chemicals flat at $1.25B
  • Operating margin 18.9% (Total segment EBIT $702M on $3.713B) vs 17.5% (Total segment EBIT $701M on $3.994B) with EBIT Reinforcement Materials $508M (-$29M) and Performance Chemicals $194M (+$30M)
+3 more insights

Risk Factors

  • Environmental compliance risk due to stricter global emission limits on nitrogen oxides, sulfur dioxide, and particulates, requiring costly capital improvements
  • Geopolitical exposure to tire production shifts from Americas/Europe to Asia reducing demand for Reinforcement Materials in higher-margin regions
+3 more insights

Financial Summary
XBRL

Revenue

$3.7B

Net Income

$331M

Gross Margin

25.3%

Operating Margin

16.7%

Net Margin

8.9%

ROE

21.4%

Total Assets

$3.8B

EPS (Diluted)

$6.02

Operating Cash Flow

$665M

Source: XBRL data from CABOT CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on CABOT CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available